SLC2A1 and cancer: Concurrently, safety-aware designs should address hepatic monitoring for FAO inhibitors (etomoxir elevates liver triglycerides by 40%) [274]; cancer risk stratification for NAD+ boosters in SLC2A1 variant carriers [275]; and immunosuppression screening for fecal transplants [276].